Scientists turn cancer cells' own carbon monoxide into a weapon that makes anticancer drugs inside tumors
RIKEN researchers use the carbon monoxide that tumor cells make to trigger a palladium catalyst that builds toxic drugs inside the cancer cells, sparing healthy ones.
Summary
Cancer treatment faces a basic problem: drugs that kill tumor cells often harm healthy tissue too. Researchers at Japan's RIKEN Pioneering Research Institute, led by Katsunori Tanaka, tested a different approach. Many cancer cells release unusually high amounts of carbon monoxide. The team used that gas as a trigger. They packed a palladium-based compound called a palladacycle inside albumin, a blood protein, to shield it from deactivation by glutathione. Inside cancer cells, the excess carbon monoxide drives a reaction that produces phenanthridinone, a molecule whose derivatives are toxic to cells and already appear in anticancer drugs. In laboratory experiments, the compound produced the drug inside cancer cells without making the same toxic products in healthy cells. The work was published in Nature Communications. It is still early, cell-based research, so it is not a treatment for patients yet. It does show a route toward safer, more selective chemotherapy alternatives.
Detailed Summary
Conventional chemotherapy kills fast-dividing cells throughout the body, which is why it causes hair loss, nausea, immune suppression and organ damage. Cancer risk rises steeply with age, and older adults often tolerate these side effects poorly. Treatments that act only inside tumors are therefore a major goal in oncology, and this study offers a new chemical strategy toward that goal.
The RIKEN team, led by Katsunori Tanaka at the Pioneering Research Institute, built on a distinctive feature of tumor biology. Many cancer cells generate unusually large amounts of carbon monoxide. Rather than treating it only as a byproduct, the researchers used it as a trigger. They designed a palladacycle, a metal-containing compound that reacts with carbon monoxide to form phenanthridinone. Certain phenanthridinone derivatives are toxic to cells and are already part of anticancer drugs.
The main obstacle was that glutathione inside cells rapidly deactivates the palladium catalyst, which stops the reaction. The team solved this by enclosing the palladacycle in albumin, a protein abundant in blood. This carrier protected the catalyst long enough for it to work inside cancer cells.
In laboratory experiments, the specially designed compound produced the toxic drug in cancer cells without generating the same toxic substances in healthy cells. The result supports the idea that relatively harmless precursors could be activated only where tumors make enough carbon monoxide.
The practical implication is a longer-term one. No patient can use this approach today, and no one should expect it in clinics soon. It is a proof of concept for tumor-selective drug manufacturing that could eventually reduce the collateral damage of chemotherapy.
Several caveats apply. The data come from early cell experiments. Animal studies, safety testing, delivery to tumors in a living body, and verification that carbon monoxide levels differ reliably across tumor types are all still needed. Palladium toxicity and the stability of the albumin carrier in vivo also remain open questions. Readers should view this as promising chemistry, not a clinical advance.
Key Findings
- Palladacycle compounds react with carbon monoxide to form phenanthridinone, a molecule whose derivatives are toxic to cells.
- Many tumors make unusually high carbon monoxide, which the approach uses as a cancer-selective trigger.
- Glutathione normally deactivates the palladium catalyst, but wrapping it in albumin protected it inside cells.
- In lab experiments, drug production occurred in cancer cells without the same toxic products appearing in healthy cells.
- The work is early-stage and cell-based, with animal and safety testing still needed before any clinical use.
Methodology
This is a ScienceDaily news report summarizing a RIKEN press release on a study published in Nature Communications. The source and journal are credible. The evidence is preclinical laboratory work on cells, and the excerpt is truncated.
Study Limitations
Findings come from early cell-based experiments and may not translate to animals or humans. The article does not detail cell types tested, efficacy numbers, or safety data, and the excerpt cuts off mid-sentence. Check the original Nature Communications paper for methods and quantitative results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: